Skip to content
Peptide research

Matrixyl

Also known as Palmitoyl Pentapeptide-4
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A topical peptide (palmitoyl pentapeptide-4) marketed to reduce fine lines and wrinkles. That benefit has solid human support, but collagen and texture claims are only moderate, and deeper repair or pigmentation claims are unproven. It appears well tolerated with minimal absorption, though data beyond 12 weeks is limited. As a cosmetic ingredient subject to FDA safety and labeling requirements, without drug approval, quality and efficacy vary by product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Matrixyl is one of the most widely used anti-aging peptides in skincare. It is a five-amino-acid signal peptide (palmitoyl pentapeptide-4) derived from collagen fragments, attached to a fatty acid chain for better skin absorption. Developed by Sederma SAS around 2000, Matrixyl works by tricking skin cells into thinking collagen has broken down, prompting them to produce new collagen, fibronectin, and other structural proteins. It is a key ingredient in numerous anti-aging serums and moisturizers worldwide.

How it works in the body

Contains palmitoyl pentapeptide-4, which mimics a fragment of collagen breakdown. When skin cells detect these fragments, they interpret it as a signal that collagen has been damaged and ramp up production of new collagen types I, III, and IV, as well as fibronectin and glycosaminoglycans for skin repair.

Research overview

Matrixyl has moderate clinical evidence supporting its anti-wrinkle claims. Lab studies confirm it stimulates fibroblasts to produce collagen types I, III, and IV, as well as fibronectin. The largest clinical trial (Robinson et al., 2005) tested it on 93 women in a 12-week double-blind study and found statistically significant improvements in fine lines and wrinkles. A small 2023 randomized trial suggested benefit, but did not confirm superiority over placebo or Argireline. A 2016 review noted that while lab evidence is strong, some clinical results only reached significance under relaxed statistical thresholds. Matrixyl works at very low concentrations (as low as 3 ppm), making it practical for consumer formulations.

Who researches Matrixyl?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • Generally very well tolerated with minimal reported side effects in clinical studies

    Low

    PMID 18492182; PMID 36909866

  • Occasional mild tingling reported, typically attributed to other formula ingredients rather than the peptide itself

    Low

    No primary source isolating tingling by ingredient; inference from the vehicle-controlled tolerability data in PMID 18492182

  • No allergic sensitization observed in repeated application studies

    Low

    PMID 41953401 (Bjerke DL et al., Curr Res Toxicol 2026, a framework for the safety evaluation of peptides in cosmetics)

  • No known systemic toxicity — topical peptide with very low systemic absorption

    Low

    PMID 25143811 (Choi YL et al., Biomol Ther 2014, dermal stability and in vitro skin permeation of KTTKS and pal-KTTKS); PMID 25033398 (Mohammed YH et al., PLoS One 2014)

  • Long-term safety data beyond 12 weeks is limited in published clinical trials

    Low

    PMID 18492182 (12 weeks); PMID 36909866 (8 weeks)

  • Efficacy may vary significantly between products due to differences in formulation, concentration, and delivery systems

    Moderate

    PMID 19393372 (Anal Chim Acta 2009, LC-MS/MS method to monitor palmitoyl peptide content in anti-wrinkle cosmetics); PMID 25033398; PMID 38399273 (Pharmaceutics 2024, liposome encapsulation of pal-KTTKS); PMID 25143811

  • As a cosmetic ingredient, manufacturing quality and concentration are not subject to pharmaceutical-grade regulation

    Moderate

    FDA, Modernization of Cosmetics Regulation Act of 2022 (MoCRA) — https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra ; content variability per PMID 19393372

Interaction summary(8)

Rated by direction with this peptide

  • Microneedling and fractional/ablative laser resurfacing

    CautionLow

    Barrier disruption substantially increases pal-KTTKS delivery into skin — microneedle pretreatment was specifically shown to enhance dermal delivery of cosmeceutically relevant peptides including pal-KTTKS by 2- to 22-fold — so applying cosmetic-grade product onto freshly treated skin bypasses the low-permeation conditions under which these products were tolerability-tested, and cosmetic formulations are neither sterile nor validated for compromised skin. Delivery enhancement is measured; the resulting tolerability risk is inferred, not studied.

    PMID 25033398 (Mohammed YH et al., PLoS One 2014, microneedle enhanced delivery of cosmeceutically relevant peptides in human skin)

  • Concurrent active dermatitis, eczema, or open wounds

    CautionLow

    Inflamed or eroded skin has a compromised barrier, which increases uptake beyond the intact-skin conditions cosmetic pal-KTTKS products were tolerability-tested under, and the peptide's wound-related data are animal and in vitro only, including a dose-dependent effect on alpha-SMA and myofibroblast transdifferentiation that the authors frame as needing a balance between healing and pro-fibrotic activity. Use on broken skin is unsupported rather than shown to be harmful.

    PMID 30603464 (Park H et al., Tissue Eng Regen Med 2017, dose-dependent effect on alpha-SMA and myofibroblast transdifferentiation); PMID 25143811

  • Topical corticosteroids (chronic use)

    CautionTheoretical

    Sustained topical steroids suppress fibroblast collagen synthesis and cause dermal atrophy, which acts directly against pal-KTTKS's proposed collagen-stimulating mechanism, so benefit would be expected to be blunted on steroid-treated skin. This is pharmacologic reasoning only — no study has examined the combination.

    Mechanistic inference from corticosteroid-induced dermal atrophy; no pal-KTTKS-specific study identified

  • Low-pH exfoliants (glycolic, lactic, salicylic acid)

    CautionTheoretical

    Acidic vehicles and acid-driven stratum corneum turnover could plausibly alter pal-KTTKS stability and residence time, and layering increases the chance of mild tingling or irritation seen with multi-active routines. No study has measured pal-KTTKS degradation or efficacy loss at low pH; published dermal stability work is mixed (skin-tissue degradation in one study, protease stability over 8 hours in another) and neither examined acidic conditions. This is a formulation-stability hypothesis, not a demonstrated interaction.

    PMID 25143811 (dermal stability and skin permeation of KTTKS and pal-KTTKS); PMID 33281001 (Errante F et al., J Pharm Biomed Anal 2021 — note this study reported the peptides stable toward proteases for up to 8 h)

  • Topical retinoids (tretinoin, retinaldehyde, retinol)

    SynergisticTheoretical

    Both stimulate dermal collagen but by non-overlapping routes — retinoids via retinoic acid receptor-driven procollagen transcription and MMP suppression, pal-KTTKS via a collagen-propeptide feedback signal to fibroblasts — so the combination is mechanistically complementary and the two are routinely co-used. No combination trial has demonstrated additive benefit, so the synergy is inferred from mechanism only; in practice retinoid irritation may reduce tolerability of the overall regimen.

    Mechanistic inference; pal-KTTKS mechanism per PMID 8486721 and clinical effect per PMID 18492182. No combination RCT identified.

  • Other cosmetic peptides (GHK-Cu, palmitoyl tripeptide-1, acetylhexapeptide-3)

    SynergisticTheoretical

    In vitro screens found defined peptide combinations activate the regenerative capacity of skin cells more than single peptides, which is the rationale behind Matrixyl 3000 style blends, but the synergy is cell-culture-level only. The one human trial comparing pal-KTTKS with acetylhexapeptide-3 tested them in separate arms, not combined, so no human evidence of combination benefit exists.

    PMID 34272744 (Int J Cosmet Sci 2021, combinations of peptides synergistically activate the regenerative capacity of skin cells in vitro); PMID 36909866

  • Niacinamide

    NeutralLow

    Widely co-formulated with pal-KTTKS in marketed anti-aging products. Niacinamide independently addresses pigmentation and barrier function, which pal-KTTKS does not, so the pairing is complementary rather than pharmacologically interactive — and niacinamide is the likely true source of the 'reduces age spots' claim attributed to Matrixyl. No study has isolated a pal-KTTKS/niacinamide interaction; the supporting literature covers each ingredient's own role and the performance of finished multi-ingredient products.

    PMID 22670614 (Br J Dermatol 2012, genomics applied to cosmetic treatment of skin ageing and discoloration — supports niacinamide's pigment/barrier role, not a peptide interaction); PMID 19735523 (J Cosmet Dermatol 2009, 3-D imaging efficacy of marketed multi-ingredient anti-aging products)

  • Systemic medications (oral drugs of any class)

    NeutralLow

    No systemic drug interaction is expected: neither KTTKS nor pal-KTTKS permeated through full-thickness human skin in vitro, the peptide is degraded in skin tissue to endogenous amino acids, and it has no documented CYP, transporter, or plasma-protein-binding activity. Clinically meaningful systemic exposure is therefore not anticipated at cosmetic use levels, though no human pharmacokinetic study has been performed.

    PMID 25143811 (dermal stability and in vitro skin permeation of KTTKS and pal-KTTKS); PMID 25033398

Known risks(7)

  • Generally very well tolerated with minimal reported side effects in clinical studies

  • Occasional mild tingling reported, typically attributed to other formula ingredients rather than the peptide itself

  • No allergic sensitization observed in repeated application studies

  • No known systemic toxicity — topical peptide with very low systemic absorption

  • Long-term safety data beyond 12 weeks is limited in published clinical trials

  • Efficacy may vary significantly between products due to differences in formulation, concentration, and delivery systems

  • As a cosmetic ingredient, manufacturing quality and concentration are not subject to pharmaceutical-grade regulation

Drug interactions(4)

  • Retinoids (tretinoin, retinol, adapalene)

    No direct interaction with Matrixyl. However, combining topical peptides with retinoids may increase skin sensitivity. Introduce combination gradually. The irritation risk comes from the retinoid, not Matrixyl.

  • Alpha-hydroxy acids (AHAs) and Beta-hydroxy acids (BHAs)

    Low pH of acid exfoliants may theoretically denature the peptide. Apply at different times of day for best results, or wait 20-30 minutes between applications.

  • Copper peptides (GHK-Cu)

    Some formulators advise against combining certain peptides in the same product due to potential competitive interactions, though clinical evidence for this is limited.

  • Vitamin C (L-ascorbic acid)

    Generally compatible. The low pH required for vitamin C stability may affect peptide integrity if applied simultaneously. Layering with a short wait time is commonly recommended.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
8
Human Studies
3

Matrixyl has strong in vitro evidence for stimulating collagen and ECM production. Clinical evidence includes a well-designed 93-subject RCT (Robinson et al. 2005) and a smaller 21-subject RCT (Aruan et al. 2023), both showing improvements in wrinkles. However, a 2016 systematic review (Aldag et al.) noted that clinical relevance remains limited, with some endpoints only significant under relaxed statistical thresholds. Efficacy is demonstrated at very low concentrations (3 ppm).

Researched for(6)

Rated by confidence in the evidence

  • Reduces fine lines and wrinkles

    High

    Two human trials, including a 12-week randomized study, showed reduced wrinkles.

    PMID 18492182 (Robinson LR et al., Int J Cosmet Sci 2005;27:155-160); PMID 36909866 (Aruan RR et al., J Clin Aesthet Dermatol 2023;16(2):37-43)

  • Stimulates collagen production

    Medium

    Well established in cell and animal studies, not yet confirmed by human skin biopsy.

    PMID 8486721 (Katayama K et al., J Biol Chem 1993;268:9941-4); PMID 38850353 (Arch Dermatol Res 2024, Pal-KTTKS-enriched carboxylated cellulose in rat burn model)

  • Improves skin texture and firmness

    Medium

    Small human trials suggest improvement, though results are less robust than for wrinkles.

    PMID 18492182; PMID 36909866

  • Promotes extracellular matrix renewal

    Low

    Supported by lab and animal studies only, with no human data on matrix turnover.

    PMID 8486721; PMID 34272744 (Int J Cosmet Sci 2021, combinations of peptides synergistically activate regenerative capacity of skin cells in vitro); PMID 38850353

  • Supports wound healing

    Low

    Limited to animal and lab studies, with mixed, dose-dependent effects observed.

    PMID 38850353; PMID 30603464 (Park H et al., Tissue Eng Regen Med 2017)

  • Reduces age spots and skin discoloration

    Speculative

    One controlled trial reported self-assessed facial improvements; objective pigmentation efficacy remains uncertain.

    No primary source identified for pal-KTTKS and pigmentation; mechanism-only inference

Benefits(6)

  • Reduces fine lines and wrinkles

    Robinson et al. (2005): 12-week RCT on 93 women showed significant wrinkle reduction vs placebo; Aruan et al. (2023): 8-week RCT confirmed crow's feet improvement

  • Stimulates collagen production

    Multiple in vitro studies show upregulation of collagen types I, III, and IV synthesis in dermal fibroblasts

  • Improves skin texture and firmness

    Robinson et al. (2005) reported significant improvement in skin texture at 4 weeks; Sederma proprietary studies confirmed anti-wrinkle efficacy including reduction of wrinkle depth, volume, and density

  • Promotes extracellular matrix renewal

    In vitro studies demonstrate increased fibronectin and glycosaminoglycan production; inhibits excess GAG production associated with aging

  • Supports wound healing

    Kachooeian et al. (2022): In vivo rat study showed wound healing improved from 63.5% to 81.81% with Matrixyl treatment, with superior collagen formation (85-89% density)

  • Reduces age spots and skin discoloration

    Robinson et al. (2005) reported significant improvement in age spots at 12 weeks

Key studies(4)

  1. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin

    Double-blind, placebo-controlled, split-face RCT93 subjects12 weeks

    Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL

    International Journal of Cosmetic Science

    2005

    Twice-daily application of pal-KTTKS cream significantly reduced fine line/wrinkle length vs placebo at weeks 8 and 12. Skin texture improved significantly at 4 weeks, age spots at 12 weeks. Well tolerated with no irritation reported.

  2. Aruan RR, Hutabarat H, Widodo AA, Firdiyono MTCC, Wirawanty C, Fransiska L

    The Journal of Clinical and Aesthetic Dermatology

    2023

    PPP-4 scores decreased 0.86 points, with no reported adverse effects. Instrument and satisfaction comparisons were nonsignificant; superiority remains preliminary.

  3. Kachooeian M, Mousivand Z, Sharifikolouei E, Shirangi M, Firoozpour L, Raoufi M, Sharifzadeh M

    ACS Omega

    2022

    Wound healing improved from 63.5% to 81.81% in Matrixyl treatment groups. Patch formulations showed superior collagen formation (85-89% density) compared to cream delivery. MTI patches produced rejuvenation of skin appendages and improved epithelialization.

  4. Aldag C, Nogueira Teixeira D, Leventhal PS

    Clinical, Cosmetic and Investigational Dermatology

    2016

    Pal-KTTKS penetrates stratum corneum, enhances collagen I secretion in vitro, and upregulates procollagen and hyaluronic acid synthase-1. However, clinical evidence of relevance remains limited; using p≤0.05, only skin texture (4 weeks) and age spots (12 weeks) showed significance.

Regulation & availability

Why researchers look at it

One of the strongest OTC anti-aging peptide evidence bases: a 93-subject double-blind trial showed significant wrinkle improvement, and a small 2023 RCT suggested benefit but left comparative superiority unconfirmed. It works at concentrations as low as 3 ppm, and virtually no reported irritation makes it unusually accessible where stronger actives like retinol cause significant sensitivity.

Estimated cost
$15-60/mo in OTC serums
FDA status
Not FDA-approved as a drug. Matrixyl is regulated as a cosmetic ingredient, not a pharmaceutical. It is not subject to FDA drug approval processes. The Cosmetic Ingredient Review (CIR) Expert Panel concluded in 2024 that palmitoyl pentapeptide-4, myristoyl pentapeptide-4, and pentapeptide-4 are safe in cosmetics as currently used. Peptides marketed for skincare occupy a regulatory gray area; the FDA has increased scrutiny of cosmetic peptides in 2025-2026, particularly regarding claims that may cross from cosmetic to drug territory. Matrixyl remains legal for cosmetic use in the US, EU, and most international markets.
WADA status
Not applicable — Matrixyl is a topical cosmetic ingredient and is not listed on the WADA Prohibited List. It has no known performance-enhancing properties and is not subject to anti-doping regulations.
Prescribability
No — Matrixyl is a cosmetic ingredient, not a prescription drug. It is available over the counter in skincare products.
Availability
Widely available over the counter in cosmetic skincare products worldwide. Matrixyl is a trademarked ingredient by Sederma SAS (now part of Croda International) and is incorporated into numerous anti-aging serums, creams, and moisturizers from brands ranging from budget (The Ordinary) to luxury (Olay, StriVectin). No prescription required. Effective concentrations in commercial products are typically 3-100 ppm (0.0003%-0.01%).

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(8)

  1. 2000
    Sederma SAS launches Matrixyl (palmitoyl pentapeptide-4) as a cosmetic anti-aging active ingredient
  2. 2005
    Robinson et al. publish landmark 93-subject RCT in International Journal of Cosmetic Science demonstrating wrinkle reduction efficacy
  3. 2007
    INCI name changed from palmitoyl pentapeptide-3 to palmitoyl pentapeptide-4
  4. Early 2000s
    Sederma introduces Matrixyl 3000, containing palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
  5. 2016
    Aldag et al. publish comprehensive literature review noting strong in vitro evidence but limited clinical relevance for matrikine peptides including Pal-KTTKS
  6. 2022
    Kachooeian et al. demonstrate Matrixyl wound healing benefits in vivo, expanding understanding beyond cosmetic anti-aging
  7. 2023
    Aruan et al. publish a small randomized trial suggesting PPP-4 benefit; superiority remains unconfirmed.
  8. 2024
    CIR Expert Panel concludes palmitoyl pentapeptide-4 is safe in cosmetics as currently used

Sources & FAQs

Research sources(6)

Frequently asked questions(6)

What is Matrixyl and how does it work?

Matrixyl (palmitoyl pentapeptide-4) is a synthetic peptide used in anti-aging skincare. It mimics collagen breakdown fragments called matrikines, which signal skin cells (fibroblasts) to produce more collagen, fibronectin, and other structural proteins. The palmitic acid chain helps it penetrate the skin barrier.

Is Matrixyl the same as Matrixyl 3000?

No. Matrixyl (original) is palmitoyl pentapeptide-4 (Pal-KTTKS). Matrixyl 3000 is a later Sederma product containing two different peptides: palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. Both target anti-aging but through somewhat different mechanisms. Matrixyl 3000 was designed to address both collagen stimulation and inflammation.

What concentration of Matrixyl is effective?

Clinical studies have demonstrated efficacy at very low concentrations — as low as 3 ppm (0.0003%) in moisturizer formulations. Most commercial products contain between 3-100 ppm. The low effective concentration makes it a cost-effective active ingredient.

Can Matrixyl be combined with retinol or vitamin C?

Yes. Matrixyl is generally compatible with other anti-aging actives including retinol, vitamin C, hyaluronic acid, and niacinamide. When combining with retinol, introduce gradually to avoid potential irritation from the retinol component (not from Matrixyl itself). Always use SPF during the day.

How long does it take to see results from Matrixyl?

Clinical studies show measurable improvements starting at 4 weeks (skin texture) with more pronounced wrinkle reduction at 8-12 weeks of twice-daily use. Individual results may vary based on skin type, age, and product formulation.

Is Matrixyl safe for sensitive skin?

Matrixyl has an excellent safety profile. Clinical trials report no irritation, no allergic sensitization, and no adverse effects. The CIR Expert Panel deemed it safe as used in cosmetics. However, overall product formulations may contain other ingredients that could cause sensitivity, so patch testing is advisable.